Current Disease Management of Primary Urethral Carcinoma
Janisch F., Abufaraj M., Fajkovic H., Kimura S., Iwata T., Nyirady P., Rink M., Shariat Sh.
European Urology Focus
Vol.5, Issue5, P. 722-734
Опубликовано: 2019
Тип ресурса: Обзор
DOI:10.1016/j.euf.2019.07.001
Аннотация:
In this review, we investigated the treatment options for primary urethral cancer. While organ-confined disease can be managed with local resection, growth beyond the organ calls for a combination of different treatment modalities, such as surgery, chemotherapy, and radiotherapy, to improve the survival of patients. © 2019 European Association of UrologyContext: Primary urethral cancer (PUC) is a rare cancer entity. Owing to the low incidence of this malignancy, the main body of literature consists mainly of case reports, making evidence-based management recommendations difficult. Objective: To review reported disease management strategies of PUC and their impact on oncological outcomes. Evidence acquisition: A systematic research was performed according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement using Medline, Scopus, and Web of Science, to find studies of the past 10 yr including ≥20 patients, and investigating treatment strategies and
Ключевые слова:
Disease management; Primary urethral carcinoma; Prognosis; Therapy; Treatment
BCG vaccine; cisplatin; doxorubicin; gemcitabine; ifosfamide; methotrexate; paclitaxel; vinblastine; bladder cancer; cancer grading; cancer growth; cancer localization; cancer prognosis; cancer radiotherapy; cancer recurrence; cancer risk; cancer staging; cystectomy; cystoscopy; distant metastasis; follow up; human; lymph node dissection; nuclear magnetic resonance imaging; overall survival; perioperative period; personalized medicine; practice guideline; preoperative period; primary urethral carcinoma; progression free survival; radical cystectomy with total urethrectomy; recurrence free survival; Review; systematic review; transurethral resection; treatment response; urethra carcinoma
Язык текста: Английский
ISSN: 2405-4569
Janisch F.
Abufaraj M.
Fajkovic H.
Kimura S.
Iwata T.
Nyirady P.
Rink M.
Shariat Sh. Sharokh 1973-
Йанисч Ф.
Абуфарай М.
Файковиc Х.
Кимура С.
Иwата Т.
Нyирадy П.
Ринк М.
Шариат Ш. Шарох 1973-
Current Disease Management of Primary Urethral Carcinoma
Текст визуальный непосредственный
European Urology Focus
Elsevier
Vol.5, Issue5 P. 722-734
2019
Обзор
Disease management Primary urethral carcinoma Prognosis Therapy Treatment
BCG vaccine cisplatin doxorubicin gemcitabine ifosfamide methotrexate paclitaxel vinblastine bladder cancer cancer grading cancer growth cancer localization cancer prognosis cancer radiotherapy cancer recurrence cancer risk cancer staging cystectomy cystoscopy distant metastasis follow up human lymph node dissection nuclear magnetic resonance imaging overall survival perioperative period personalized medicine practice guideline preoperative period primary urethral carcinoma progression free survival radical cystectomy with total urethrectomy recurrence free survival Review systematic review transurethral resection treatment response urethra carcinoma
In this review, we investigated the treatment options for primary urethral cancer. While organ-confined disease can be managed with local resection, growth beyond the organ calls for a combination of different treatment modalities, such as surgery, chemotherapy, and radiotherapy, to improve the survival of patients. © 2019 European Association of UrologyContext: Primary urethral cancer (PUC) is a rare cancer entity. Owing to the low incidence of this malignancy, the main body of literature consists mainly of case reports, making evidence-based management recommendations difficult. Objective: To review reported disease management strategies of PUC and their impact on oncological outcomes. Evidence acquisition: A systematic research was performed according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement using Medline, Scopus, and Web of Science, to find studies of the past 10 yr including ≥20 patients, and investigating treatment strategies and